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Although H. pylori infection has been recognized as a major etiological agent
for the development ofchronic active gastritis, duodenal ulcer and benign non-
NSAID related gastric ulcer, its role in the development ofsymptoms inpatients
with dyspepsia remains uncertain. Results from population-based epidemiolog-
ical studies have been conflicting regarding a causal link between H. pylori
infection and dyspepsia. Abnormalities in gastric acid secretion may exist in
some dyspeptic patients. Whether disordered gastric motility seen in dyspeptic
patients is related to the infection is not clear based on the results in the litera-
ture. Numerous clinical trials have been undertaken to eradicate H. pylori infec-
tion and improve the symptoms in dyspeptic patients; however, the results have
been discrepant between studies. Many published studies suffer from method-
ological problems that have made interpretation difficult. Large, well-conduct-
ed, randomized, placebo-controlled, clinical trials with long-term follow-up are
needed tojustify the beneficial effect ofH. pylori eradication treatment in dys-
peptic patients seen in some small studies. H. pylori eradication therapy is cost-
effective in H. pylori-infected dyspeptic patients although this benefit may take
a long time to accrue, especially in younger patients.
INTRODUCTION
Dyspepsia, defined by an International Working Group as "persistent or recurrent
abdominal pain or abdominal discomfort (a subjective, negative feeling) centered in
(mainly localized to) the upper abdomen" [1], is very common in the developed and the
developing world. Approximately one in four adults in the United States andAustralia and
40 percent in the United Kingdom suffer from various dyspeptic symptoms [2-4]. The
prevalence is higher in some developing countries [5, 6]. However, among the majority of
patients, no evidence of organic disease will be found [7], and a diagnosis of non-ulcer
dyspepsia (NUD)b will be made in these patients [8].
Helicobacterpylori infection also is very common in the general populations ofwest-
ern countries. Epidemiological studies have shown that about 30 to 60 percent of NUD
patients are infected with H. pylori [9-11]. However, the results in the literature regarding
a causal association between H. pylori infection and NUD are conflicting [12]. Moreover,
whether treatment to eradicate the infection is beneficial to the improvement ofdyspeptic
symptoms remains inconclusive. Many clinical trials sufferfrommethodological problems
making interpretation difficult [13]. This article aims to discuss whether H. pylori infec-
tion may have any causal link to the development ofsymptoms in patients with dyspepsia;
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FRCPC, FACG, Professor of Medicine, Department of Medicine, Division of Gastroenterology,
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what the possible mechanisms might be; whether the infection should be eradicated and
what management strategies should be considered to relieve symptoms in patients with
dyspepsia and NUD.
IS THERE A CAUSAL LINK BETWEEN H. PYLORI
INFECTIONAND DYSPEPSIA
The published epidemiological studies provide equivocal results regarding arelation-
ship between H. pylori infection and dyspepsia. Some studies report a difference in H.
pylori prevalence between dyspeptics and controls [14-16], whereas others show the
infection to be more common in asymptomatic controls [17, 18]. Unfortunately, many
studies suffer from serious flaws in study design including the representativeness of the
control group to the general population to which the dyspeptic patients belonged. Most
studies have not used race, age- and sex- matched controls [12, 13], which are strongly
related to theprevalence ofH.pyloriinfection inthe general population [19, 20]. This also
is the case in dyspeptic patients in which the prevalence of H. pylori infection increases
with advancing age [18, 21]. A recent review combined 19 epidemiological studies pub-
lished between 1987 and 1994 and found a relative risk of 2.3 (95 percent confidence
intervals 1.9-2.7) for a link between H. pylori infection and NUD irrespective of study
quality [22].
An interesting study from Italy has shown a positive relation between H. pylori sero-
prevalence and the frequency ofdyspeptic symptoms [23]. In 124 subjects, whose spouse
had been diagnosed with H. pylori positive duodenal ulcer, 88 (71 percent) were found to
be seropositive by IgG antibodies against H. pylori infection compared with 145 of 248
(58 percent) age- and sex-matched healthy controls. Of 88 H. pylori-positive spouses, 30
percent had a history of chronic or recurrent upper gastrointestinal symptoms, whereas
only 11 percent of sero-negative spouses experienced similar symptoms [23]. Another
prospective study also found that subjects who became infected with H. pylori were four
times more likely to have upper gastrointestinal symptoms than H. pylori-negative con-
trols although the sample size was small [24].
Dyspeptic symptoms have been divided into three general subgroups based on which
symptoms are predominant: namely, ulcer-like, reflux-like and dysmotility-like symp-
toms. It has been suggested that H. pylori infection may be more commonly associated
with ulcer-like dyspepsia than with dysmotility-like symptoms [15, 25]. However, most
studies have failed to demonstrate any association between individual symptoms and H.
pylori status [12, 26]. Furthermore, many symptoms overlap, and the severity of symp-
toms between individuals varies significantly, indicating a complex relationship between
H. pylori infection and dyspepsia, if any.
PATHOPHYSIOLOGY OF DYSPEPTIC SYMPTOMS
AND H. PYLORI INFECTION
The pathogenesis of dyspepsia remains uncertain, although abnormalities involving
theregulation ofgastric acid secretion, disordered gastric motility and alteredvisceral per-
ception to gastric stimuli, gastric mucosal inflammation, psychological and environmen-
tal factors and H. pylori infection alone ortogether have all been considered possible can-
didates [22, 27-29]. It is likely that a constellation of factors leads to the development of
the symptom complex ofdyspepsia (Figure 1).
Could H. pylori infection be considered the triggerforthe development ofdyspepsia?
There is evidence to show that a substantial proportion of NUD patients with H. pylori
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infection have abnormalities of gastric acid secretion similar to duodenal ulcer patients
[27]. In a well-designed study, El-Omar et al. compared 25 H. pylori-infected NUD
patients with 25 H. pylori-positive asymptomatic subjects, 25 H. pylori-negative healthy
controls and 25 H.pylori-infected duodenal ulcerpatients. They found that gastrin-releas-
ing peptide-stimulated gastric acid secretion in the infected NUD patients was 1.5 times
that of the H. pylori-positive asymptomatic controls and five times that of the H. pylori-
negative healthy controls, although the median acid output was lower than that of H.
pylori infected duodenal ulcer patients [27]. However, since this study did not include H.
pylori-negative NUD patients, the generalizability of the results needs to be confirmed.
Furthermore, it is not known whether eradication of H. pylori infection will restore the
abnormal response of acid secretion to GRP stimulation, although this would be antici-
pated from the results in duodenal ulcer patients [30].
Dyspeptic patients have a spectrum ofmotordisturbances including an increased gas-
tric perception to distension, antral hypomotility and delayed gastric emptying [31-33].
However, results regarding the relation ofH. pylori infection to the altered gastric motili-
ty in NUD patients have been conflicting. Some studies suggested thatH.pylori infection
is associated with delayed [34, 35] or accelerated gastric emptying [36]; however, the
majority of studies have not shown any association between the H. pylori status ofNUD
patients and gastric motility [37-40]. This may be due to mild gastric mucosal inflamma-
tion with less dense H.pylori infection in dyspeptic patients, since there is some evidence
to suggest that the degree ofmucosal inflammation is associated with the number ofbac-
teria [41], and sensory abnormalities have been linked to a subgroup ofpatients with high
anti-H. pylori titers [33]. H. pylori-induced mucosal inflammation and the subsequent
release of chemokines and cytokines may excite neurons and increase pain sensation
through the release of mucosal prostaglandin E2 as has been shown in a rabbit ear pain
model [42]. IL-Ii increases enteric neural sensitivity and stimulates IL-1, IL-6 and TNF-
a secretion by intestinal smooth muscle cells (for review see [22]). Chronic inflammation
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Figure 1. Postulated mechanisms for H. pylori-initiated inflammation to disturb antro-pyloro-
duodenal function. (Reproduced from: Talley, N.J. and Hunt, R.H. Gastroenterology 113:S67-
S77, 1997. (With permission).
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ofthe gastric mucosa may alter enteric nerve and smooth muscle cell function [43]. Thus,
a subgroup of H. pylori-infected dyspeptic patients with severe mucosal inflammation
may be linked to dyspeptic symptoms.
Increased mucosal permeability permits the entry ofantigens to the mucosa, not only
H. pylori related antigens, but also food-derived antigens that could result in altered
mucosal function even after H. pylori eradication [44].
RESULTS OF CLINICAL TRIALS
The NIH Consensus Conference in 1994 didnotrecommenderadication treatmentfor
dyspeptic patients infected with H. pylori [45]. Indeed, the results of studies in the litera-
ture are conflicting regarding improvement in dyspeptic symptoms after treatment for H.
pylori infection in dyspeptic patients. As critically reviewedbyTalley and van Zanten [13,
46], previous studies have many methodological problems and provide data of variable
quality, and it is difficult to draw a firm conclusion. A recent meta-analysis combining
results from 10 studies, though open to criticism, showed that H. pylori eradication treat-
ment improved dyspeptic symptoms [47]. Symptom improvement was more evident after
a mean follow-up of longer than 12 months [47]. This is in agreement with the histologi-
cal changes seen in patients after successful treatment ofthe infection [48]. These results
suggest that a subgroup of dyspeptic patients might benefit from eradication treatment
over a longer time period than has been observed in most studies to date.
Numerous clinical trials with different drug combinations have been undertaken in an
attempt to relieve symptoms in dyspeptic patients. In studies that compared the effect of
different bismuth salts with placebo on the improvement of dyspeptic symptoms, poor
study quality and the difficulty of blinding studies in patients treated with bismuth have
made the results difficult to interpret [13]. In a well-designed, placebo-controlled trial,
Marshall et al. compared the effect ofbismuth subsalicylate (BSS) 512 mg qid and place-
bo given for 3 weeks after atwo-weekplacebo run-in period in 50H.pylori-infected NUD
patients [49]. They found that 70 percent ofthe infection was cleared in the BSS treatment
group, and the histological improvement in gastritis paralleled H. pylori suppression.
Lower symptom scores and fewer symptomatic days were seen in patients treated with
BSS when compared to patients in the placebo group, but the difference was not signifi-
cant due to a large overlap ofconfidence intervals between the two groups [49].
Most studies report that suppression of H. pylori infection with bismuth salts corre-
lated with symptomatic improvement [13]. This may result from the improvement in his-
tological gastritis. One study, reported by Kang, has shown that, in parallel with the sup-
pression of H. pylori infection, significantly more patients benefitted from bismuth (De-
Nol) treatment than from placebo when histological gastritis was present, whereas there
was no difference between the two groups in patients without histological gastritis [50].
It may be argued that the poor effect oftreatment with a single bismuth agent results
from a lowereradication rate ofH. pylori infection [51] sincehistological gastritis, togeth-
er with an increase in the number of bacteria in the stomach, recurred rapidly after dis-
continuation oftreatment [49]. Furthermore, many early studies only followed patients up
to three months [47]. This may be too short a period offollow-up to see a possible differ-
ence between patients with and without H. pylori infection after eradication treatment.
Several recent studies have prolonged the observation period up to nearly three years fol-
lowing cure of the infection [52-55]. McCarthy et al. prospectively studied the effect of
eradication of H. pylori infection with colloidal bismuth subcitrate (CBS) or metronida-
zole plus amoxicillin or CBS plus metronidazole and amoxicillin on the symptoms of 83
H. pylori-positive NUD patients followed for one year [53]. They found that H. pylori
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eradication therapy significantly improved symptom scores at four weeks after treatment
compared to those at entry. This was more significant in patients in whom the infection
was cured [53]. At one year, the symptom scores returned almost to baseline in patients
with persistent infection, whereas a significant and continued fall in the scores was seen
in patients cured [53]. Furthermore, the sustained symptom improvement correlated with
the higher eradication rate of the infection in those treated with the three drug combina-
tion. These results suggest apossible role ofH. pyloriinfection in the developmentofdys-
peptic symptoms in NUD patients, although this study suffered from several methodolog-
ical problems including lack of randomization and no placebo control group. In a better
designed and randomized, placebo-controlled study, eradication ofH. pylori infection did
not improve dyspeptic symptoms in NUDpatients when compared toplacebo at six weeks
or six months following treatment, although both groups showed a good response to treat-
ment at week six [56]. However, this could have been due to the shorter time of follow-
up.
In a study from Italy, Lazzaroni et al. randomized 41 NUD patients to treatment with
either four-week CBS plus one-week metronidazole or placebo and compared the histo-
logical change in the severity of gastritis and clinical improvement in symptom scores
[52]. Eradication ofH. pylori infection was achieved in 64 percent (16/25) ofthe patients
treated with dual therapy and 25 percent (6/24) with CBS plus placebo. In the dual thera-
py group, a significant improvement in the histological gastritis at eight and 24 weeks
post-therapy was seen in patients cured, but not in those with persistent infection. This
also was the case in the CBS plus placebo group [52]. Eradication ofH. pylori infection
correlated significantly with the decrease in symptom scores in NUD patients especially
at 24 weeks after treatment compared to those with the infection [52]. However, there was
no association between H. pylori status and symptom subgroups (ulcer-like and dysmotil-
ity-like) in symptom scores before or after treatment [52]. A similar result was reported
by Sheu et al. who compared the long-term effect of H. pylori eradication on symptom
relief and gastritis in 41 young NUD patients (< 45 years) treated with CBS-based triple
therapy or H2-receptor antagonist and confirmed that eradication of the infection
improved in both symptom and gastritis scores [54]. Indeed, there seems to be a correla-
tion between the suppression of H. pylori infection and an improvement in dyspeptic
symptoms [22], although contrasting reports do exist in the literature [55, 57]. Large mul-
ticenter, well-conducted, randomized clinical trials with long-term follow-up (> 1 year)
are needed to clarify this issue further.
MANAGEMENT STRATEGIES FOR H. PYLORI
INFECTION IN PATIENTS WITH DYSPEPSIA
The optimal management of patients with dyspepsia is controversial. There is now
evidence to show that eradication of H. pylori infection would benefit most dyspeptic
patients infected withH.pylori. To testby serology forevidence ofH. pylori infectionfirst,
or to use empirical antisecretory medications, or to undergo endoscopy are the key ques-
tions in daily practice. Several decision and cost-effective analysis studies have addressed
this issue [58-61]. Silverstein et al. evaluated, by decision analysis andcomprehensive sim-
ulation experiments, the long-term outcome ofthe two most frequent management strate-
gies for patients with dyspepsia ofunknown cause: initial endoscopy before medical ther-
apy and empirical treatment with an H2-receptor antagonist before endoscopy [58]. They
found a difference of 1.8 percent of total cost between initial endoscopy and empirical
treatment. However, initial non-invasive testing forH. pylori has lower charges than initial
endoscopy if H. pylori- infected patients are treated with antimicrobials without prior
endoscopy. In other words, ifpatients with H. pylori infection routinely have endoscopy,
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the cost would be much higher than initial serological testing for the infection and antimi-
crobial treatment [58]. Ofman's study reported a similar result suggesting that initial anti-
H. pylori therapy is the most cost-effective management strategy in H. pylori-seropositive
patients with dyspepsia [59].
Few studies have examined the cost-effectiveness of testing for H. pylori infection
and initial empiric treatment in patients with dyspepsia. Sonnenberg found that the cost-
benefit relationship of serological screening for H. pylori in dyspeptic patients is influ-
enced primarily by the response rate of nonulcer dyspepsia to H. pylori eradication and
secondly by the monetary benefit ofulcerprevention in H. pylori positive patients [61]. A
response to H. pylori eradication in 5 to 10 percent of all patients with dyspepsia would
make screening and treatment for H. pylori a beneficial option [61]. Furthermore, poten-
tial benefits associated with H. pylori eradication may outweigh the risk of continued H.
pylori exposure in some patients and may prevent progression to peptic ulcer disease,
MALT lymphoma or gastric adenocarcinoma. Therefore, the decision to test for and treat
H. pylori infection should be made on a case-by-case basis. Testing forH. pylori infection
is only recommended if eradication treatment is planned. For patients who present with
previously uninvestigated dyspepsia in whom a diagnosis of organic disease is possible,
testing for H. pylori or together with other investigations to establish the clinical diagno-
sis should be considered. For those with alarm symptoms such as weight loss, bleeding,
anemia or dysphagia, a formal diagnostic evaluation by endoscopy should be undertaken.
In conclusion, H. pylori infection and patients with dyspeptic symptoms are both
widely prevalent in the general population. There is evidence to suggest that eradication
of H. pylori may benefit dyspeptic patients over a long term. However, well-conducted,
long-term clinical trials areneeded to assess the effectiveness ofsuch treatments, improve-
ment ofdyspeptic symptoms and cost.
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